Lapatinib, 98%, a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively

Name: Lapatinib, 98%, a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively | 231277-92-2
Brand: J&K Chemical
SKU: JK831262_200_MG
Price: 326.0 USD
Availability: OutOfStock

Cat. No JK831262_200_MG

Vendor: J&K Chemical

Product Information

Product Name

Lapatinib, 98%, a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively

Brand Name

J&K

Product Number

831262

CAS

231277-92-2

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

208908

IUPAC Name

N-3-chloro-4-(3-fluorophenyl)methoxyphenyl-6-5-(2-methylsulfonylethylamino)methylfuran-2-ylquinazolin-4-amine

InChI Key

BCFGMOOMADDAQU-UHFFFAOYSA-N

SMILES

CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl

Safety Information

Storage Condition

Freezer -20℃

References Data Source From Pubchem

The Impact of Conventional Chemotherapy Regimens and Targeted Drugs on Ovarian Function in Breast Cancer Patients

Publication Name: Reproductive sciences (Thousand Oaks, Calif.)

Publication Date: 2026-03-02

DOI: 10.1007/s43032-026-02067-x

Lapatinib-Loaded Glucose-Functionalized Silver Nanoparticles Enhance Efficacy in HER2-Positive Breast Cancer Cells and Modulate Survival-Associated Genes

Publication Name: Pharmaceutical Research

Publication Date: 2026-02-26

DOI: 10.1007/s11095-026-04056-w

Enhancing healthcare economics: the impact of manual dose rounding on T-DM1 costs in breast cancer treatment

Publication Name: Drugs & Therapy Perspectives

Publication Date: 2026-02-22

DOI: 10.1007/s40267-026-01219-y

HER2 heterogeneity between primary cancers and brain metastases: a retrospective analysis of 185 matched pairs across multiple cancer types

Publication Name: Journal of Neuro-Oncology

Publication Date: 2026-02-20

DOI: 10.1007/s11060-026-05476-9

Discovery of quinazoline-based derivatives as novel autophagy inhibitors in pancreatic cancer

Publication Name: Medicinal Chemistry Research

Publication Date: 2026-02-19

DOI: 10.1007/s00044-026-03533-6

Lapatinib, 98%, a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively

Product Information

General Information

Safety Information

References Data Source From Pubchem

The Impact of Conventional Chemotherapy Regimens and Targeted Drugs on Ovarian Function in Breast Cancer Patients

Lapatinib-Loaded Glucose-Functionalized Silver Nanoparticles Enhance Efficacy in HER2-Positive Breast Cancer Cells and Modulate Survival-Associated Genes

Enhancing healthcare economics: the impact of manual dose rounding on T-DM1 costs in breast cancer treatment

HER2 heterogeneity between primary cancers and brain metastases: a retrospective analysis of 185 matched pairs across multiple cancer types

Discovery of quinazoline-based derivatives as novel autophagy inhibitors in pancreatic cancer